title: Role of exclusive chemotherapy as first line treatment in oligodendroglioma.
abstract: OBJECTIVE
  The optimal therapy of oligodendrogliomas remains uncertain. Although chemosensitive, these tumors are not chemocurable. We investigated whether chemotherapy delays the need for radiation therapy (RT) without decreasing length and quality of survival.
  
  
  METHODS
  Among 89 patients treated for oligodendrogliomas at the Centre Léon Bérard of Lyon from 1982 to 1999, 59 patients fitted inclusion criteria, having had centrally reviewed pure oligodendroglioma requiring treatment. According to the WHO's classification 35 patients had Grade III and 24, Grade II oligodendrogliomas.
  
  
  RESULTS
  According to the intent to treat, patients were retrospectively classified in three groups as exclusive RT (Group 1), radio-chemotherapy (Group 2), or exclusive chemotherapy (Group 3). Median progression-free survival (PFS): was 47 months [95% confidence interval (CI) 39-56], and median overall survival (OS) was 109 months (95% CI 83-134). In univariate analysis, PFS was correlated with frontal location and WHO classification; OS was correlated with frontal location and Post-operative Karnosky performans status both appearing as independent prognostic factors for OS in multivariate analysis. There was no significant difference between the treatment groups with regard to PFS (P = 0.82) and OS (P = 0.64). In the group of patients treated with exclusive chemotherapy the 5-year PFS and OS rates were 44 and 71%, respectively.
  
  
  CONCLUSIONS
  Front-line exclusive chemotherapy results in prolonged OS in patients with confirmed pure oligodendroglioma. Whether this strategy improves quality of life remains debatable.
authors.affiliation: Radiotherapy and Neuro-Oncology Unit, Centre Léon Bérard, Lyon, France. sunyach@lyon.fnclcc.fr
authors.forename: Marie Pierre
authors.initials: MP
authors.lastname: Sunyach
authors.forename: Anne
authors.initials: A
authors.lastname: Jouvet
authors.forename: David
authors.initials: D
authors.lastname: Perol
authors.forename: Emmanuel
authors.initials: E
authors.lastname: Jouanneau
authors.forename: Jacques
authors.initials: J
authors.lastname: Guyotat
authors.forename: Laurence
authors.initials: L
authors.lastname: Gignoux
authors.forename: Christian
authors.initials: C
authors.lastname: Carrie
authors.forename: Didier
authors.initials: D
authors.lastname: Frappaz
mesh_terms: D000328:Adult; D000368:Aged; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy*; D015331:Cohort Studies; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D005260:Female; D005625:Frontal Lobe / Q000473:pathology; D006801:Humans; D008297:Male; D008875:Middle Aged; D009837:Oligodendroglioma / Q000188:drug therapy* / Q000532:radiotherapy*; D012189:Retrospective Studies; D018709:Statistics, Nonparametric; D016896:Treatment Outcome